Protocol Ledger

NCT07499232 · Phase III · RECRUITING

A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

Interventional Phase III clinical trial protocol NCT07499232 sponsored by Johnson & Johnson / Janssen in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-04-21 Enrollment: 530 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07499232
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)530 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07499232
Protocol FieldVerified Registry Value
NCT IdentifierNCT07499232
Consolidated Lead SponsorJohnson & Johnson / Janssen
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment530 participants (ESTIMATED)
Registered Start Date2026-04-21
WhyStopped ClassificationNot Stopped

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI